HERMOSTON RAPPEUMASAIRAUKSIEN IMMUNOLOGISEEN SÄÄTELYYN PERUSTUVAT PIENMOLEKYYLIT. Nerve degeneration diseases immunologically BASED ON REGULATORY small molecules

https://neurodegenerationresearch.eu/survey/hermoston-rappeumasairauksien-immunologiseen-saatelyyn-perustuvat-pienmolekyylit-nerve-degeneration-diseases-immunologically-based-on-regulatory-small-molecules/

Principal Investigators

Jari Koistinaho

Institution

University of Eastern Finland

Contact information of lead PI
Country

Finland

Title of project or programme

HERMOSTON RAPPEUMASAIRAUKSIEN IMMUNOLOGISEEN SÄÄTELYYN PERUSTUVAT PIENMOLEKYYLIT. Nerve degeneration diseases immunologically BASED ON REGULATORY small molecules

Source of funding information

Tekes

Total sum awarded (Euro)

€ 292,600

Start date of award

01/07/2015

Total duration of award in years

2

Keywords
Research Abstract

Central nervous system degenerative diseases and a significant part of the macular degenerative diseases are common and the number of patients suffering from these to grow over the next few decades. These diseases do not have effective medical treatment. Although basic research has found a number of the body’s own proteins, administration of which to patients might be useful, however, is the use of such “biological drugs” generally proved to be difficult. On the other hand question. effects of proteins in the development of small-molecule drugs mimic is difficult, because the effect of sections of biological proteins are too large and complex. In this project, we are developing a new drug development strategy, which allows the complex effect of the biological section of the protein is skipped and the effect of small molecule targeted to simple, from their point of biological protein downstream from the distance. We have found that the body’s anti-inflammatory therapeutic protein for regulating the number of different models of brain diseases including cerebral infarction. Ko. inflammatory protein regulating mechanisms of investigating the Academy of Finland funded 4-year project. In this study, we combine biotechnology to develop the company’s expertise in five different degenerative diseases of the nervous system of new drug development tools. The main goal is to show that co-biotech companies and academic research groups, it is possible to develop a new way micromolecular drugs, which is a power of biological protein, but whose medicinal use could be possible.

Further information available at:

https://www.uef.fi/en/-/uusi-hoito-aivojen-tulehdustilaan-sai-tekesin-kaupallistamistukea

Types:
Investments < €500k

Member States:
Finland

Diseases:
N/A

Years:
2016

Database Categories:
N/A

Database Tags:
N/A